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patients were transplanted without serotherapy. The most frequent
mismatch in our cohort of the patients was single mismatch on C
locus (28%), followed by combined mismatch in class I and II
(24%). Multiple mismatch in class I was present in 19% and 1
single mismatch on A or B loci in 8% of the patients. Seven percent
of the patients received graft with 2 mismatches on C, while 7%
received graft with 1 and 7% with multiple mismatch in class II
HLA. Results: 34 patients developed GVHD (Gr I-38%, Gr
II-38%, Gr III-12%, and Gr IV-12%). Forty-one patients died
after BMT; 40% for relapse, 31% for infection, 18% for GVHD,
and 11% due to VOD. Three year probability of survival is 40%
for AML, 60% for CML, 75% for ALL, and 30% for MDS
patients. Three-year probability of survival of the 17 patients, 14 of
whom in advanced stage of the disease, who received graft mis-
matched for DRB1, is 50%. Summary: BMT from partially
matched alternative donors offer chance for the patients without
fully (10/10) matched donor. ATG in conditioning decreases the
risk of severe GVHD (24% Gr IIIIV). Relapse and infection
were the most common causes of treatment failure in our cohort of
the patients.
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UMBILICAL CORD BLOOD TRANSPLANTATION VERSUS UNRELATED
DONOR BONE MARROW TRANSPLANTATION IN ADULT AND PEDIAT-
RIC PATIENTS
Hwang, W.Y.K.1, Samuel, M.2, Tan, D.C.L.1, Koh, L.P.1, Linn, Y.C.1
1. Singapore General Hospital, SingHealth, Singapore, Singapore; 2.
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Several studies have been performed to compare the results of
unrelated donor bone marrow transplantation (UBMT) with un-
related donor cord blood transplantation (UCBT). In order to
objectively analyze these data, we performed a systematic review
and meta analysis of pooled data on comparative studies on unre-
lated donor BMT versus UCBT to evaluate if UCBT is equivalent
to BMT in patients requiring a haematopoietic stem cell trans-
plant. Combining the studies, 161 children and 331 adults under-
going UCBT (mostly 1-2 antigen mismatched), as well as 316
children and 646 adults undergoing UBMT (almost entirely fully
matched with the recipient) were analyzed. Post-transplant en-
graftment of neutrophils and platelets occurred slower and more
infrequently with UCBT, although the difference was only in the
order of 10–20%. Two to 3 year overall survival was equivalent in
children undergoing UCBT (35 to 59%) compared to those who
had matched unrelated donor BMT (41 to 57%). In pooled com-
parisons of the studies between UCBT and UBMT in children,
chronic graft-versus-host disease (GVHD) was less with UCBT
(pooled estimate 0.26, CI 0.12–0.57, P  .0007) although grade
III–IV acute GVHD (pooled estimate1.46, CI 0.42–5.03) was no
different. There was a trend towards lower overall mortality in
children undergoing UCBT (pooled estimate 2.12, CI 0.94–4.77,
P  .07). For adults, relapse rates (pooled estimate 0.86, CI 0.62–
1.19), transplant related mortality (pooled estimate 1.04, CI 0.52–
2.08) and disease free survival (pooled estimate 0.59, CI 0.18–1.96)
were not statistically different. In conclusion, pooled analysis of
comparative studies in children and adults revealed that 1-2 anti-
gens mismatched UCBT had consistently equivalent survival out-
comes when compared with fully matched unrelated donor BMT.
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To expand the donor pool, allogeneic stem cell transplantation
(SCT) using HLA 2-3 antigen-mismatched (haploidentical) related
donors has been studied. To date, there are a few reports describ-
ing nonmyeloablative stem cell transplantation (NST) from HLA-
haploidentical donors. We recently showed that a nonmyeloabla-
tive regimen consisting of ﬂudarabine, busulfan, and ATG was
sufﬁciently immunosuppressive to achieve donor type engraftment
in transplantation from HLA-haploidentical donors who had 1
antigen-mismatch in the GVH direction and 2-3 antigen-mis-
matches in the HVG direction (Leukemia, 2003). In that study,
however, acute GVHD could not be sufﬁciently controlled with a
GVHD prophylaxis using cyclosporine or tacrolimus. We have
been testing a protocol for HLA-haploidentical NST from 2-3
antigen-mismatched donors in the GVH direction without T-cell
depletion using more intensiﬁed GVHD prophylaxis (tacrolimus
and methylprednisolone). Methods: We performed an HLA-hap-
loidentical NST from 2-3 antigen-mismatched donors in the GVH
direction. Between Jan 2000 and July 2005, 30 patients with he-
matologic malignancies, including AML, ALL, CML, and NHL,
underwent allogeneic SCT in Osaka University Hospital. The
median age of the patients was 50 (range 28–63). All patients
except for 3 patients with Philadelphia chromosome were in ad-
vanced stage at the time of transplantation. Four patients had a
prior autologous SCT, and all of them underwent HLA-hap-
loidentical NST because of recurrence of the original disease.
Preconditioning regimen consists of ﬂudarabine (30 mg/m2  6),
busulfan 4 mg/kg  2, and rabbit ATG (Fresenius) 2 mg/kg  4.
GVHD prophylaxis regimen consists of tacrolimus 0.02 mg/kg/day
and methylprednisolone 1 mg/kg/day from day 0. Results: All
patients except for one achieved donor type engraftment. The
patient who had a rejection was successfully rescued with second
transplantation from the same donor. Fifteen patients did not
develop acute GVHD clinically, and only 5 patients developed
grade II GVHD. The main causes of death were relapse and
thrombotic microangiopathy. The overall survival at 3 years was
49.2 % at a median follow-up of 664 days (range, 37–1918 days).
Conclusions: HLA-haploidentical NST may be feasible for pa-
tients who are at high risk and lack available donors, and who are
considered ineligible for myeloablative regimens because of ad-
vanced age or comorbidities, although our results have to be
conﬁrmed in a large-scale study.
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The German Consensus for matching allogeneic donors of he-
matopoietic progenitor cell (1996/2000) recommends matching
donors for HLA-A,B on serological level (2 digit allele level match-
ing within split groups for B15, B40) and by allele level for DRB1
and, if possible, DQB1. We have retrospectively performed se-
quencing based HLA-A,B,C analyses for 262 adult unrelated donor
recipient pairs matching for A, B, and DRB1 according to the
above deﬁnition in order to see if outcome could be improved by
more stringent selection criteria. Accepted diagnoses were ALL
(21%), AML (39%), CML (33%), and MDS (7%). Sixty percent of
the patients were male with a median age of 38 (range 18–67)
whereas 67% of the donors were male with a median age of 36
(range 19–58). The patients were transplanted in Berlin (56),
Erlangen (6), Hannover (9), Heidelberg (18), Mainz (56), Munich
(50), Regensburg (13), Ulm (11), and Wiesbaden (43) using het-
erogeneous regimens for conditioning and GvHD-prophylaxis.
After analyzing the relevant covariates, we stratiﬁed the Cox pro-
portional hazard model for patient age ( 	 median), diagnosis,
and disease phase (early 145, advanced 117). We found 20 pairs
with an allele level difference for A, 43 for B, 112 for C, and 20 for
DQB1. The only signiﬁcant detrimental effect for survival was
seen for allele level differences of HLA-B with R  1.56 (1.01 . . .
2.41) and P  .05. The survival curves did not suggest an inﬂuence
of any other HLA difference mentioned except for advanced dis-
ease where allele differences of HLA-A or C may be beneﬁcial,
probably due to a GvL effect. Study supported by the German Jose´
Carreras Leukemia Foundation.
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